Lee KS - Search Results

1

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.

Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Winer EP, et al. Among authors: lee ks. Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4. Lancet Oncol. 2021. PMID: 33676601 Clinical Trial.

2

Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.

Park IH, Ro J, Lee KS, Kim SN, Yun YH, Nam BH. Park IH, et al. Among authors: lee ks. Invest New Drugs. 2010 Oct;28(5):659-69. doi: 10.1007/s10637-009-9285-x. Epub 2009 Jul 4. Invest New Drugs. 2010. PMID: 19575146 Clinical Trial.

3

Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.

Jung SY, Kim SK, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Park IH, Lee KS, Shin KH, Lee S, Kim SW, Kang HS, Ro J. Jung SY, et al. Among authors: lee sj, lee ks, lee s. Ann Surg Oncol. 2010 Jan;17(1):247-53. doi: 10.1245/s10434-009-0710-3. Epub 2009 Sep 24. Ann Surg Oncol. 2010. PMID: 19777177 Clinical Trial.

4

Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.

Park IH, Ro J, Lee KS, Kim EA, Kwon Y, Nam BH, Jung SY, Lee S, Kim SW, Kang HS. Park IH, et al. Among authors: lee ks, lee s. J Clin Oncol. 2010 Jun 1;28(16):2705-11. doi: 10.1200/JCO.2009.26.5884. Epub 2010 Apr 26. J Clin Oncol. 2010. PMID: 20421538 Clinical Trial.

5

High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

Rhee J, Han SW, Cha Y, Ham HS, Kim HP, Oh DY, Im SA, Park JW, Ro J, Lee KS, Park IH, Im YH, Bang YJ, Kim TY. Rhee J, et al. Among authors: lee ks. Breast Cancer Res Treat. 2011 Jan;125(1):107-14. doi: 10.1007/s10549-010-1200-9. Epub 2010 Oct 9. Breast Cancer Res Treat. 2011. PMID: 20936340

6

Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.

Min SY, Lee SJ, Shin KH, Park IH, Jung SY, Lee KS, Ro J, Lee S, Kim SW, Kim TH, Kang HS, Cho KH. Min SY, et al. Among authors: lee sj, lee ks, lee s. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e697-705. doi: 10.1016/j.ijrobp.2010.10.014. Epub 2010 Dec 2. Int J Radiat Oncol Biol Phys. 2011. PMID: 21129858

7

Outcomes of positron emission tomography-staged clinical N3 breast cancer treated with neoadjuvant chemotherapy, surgery, and radiotherapy.

Park HJ, Shin KH, Cho KH, Park IH, Lee KS, Ro J, Jung SY, Lee S, Kim SW, Kang HS, Chie EK, Ha SW. Park HJ, et al. Among authors: lee ks, lee s. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e689-95. doi: 10.1016/j.ijrobp.2010.11.061. Epub 2011 Feb 6. Int J Radiat Oncol Biol Phys. 2011. PMID: 21300467

8

Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to St Gallen consensus and intrinsic subtypes.

Jung SY, Jeong J, Shin SH, Kwon Y, Kim EA, Ko KL, Shin KH, Ro J, Lee KS, Park IH, Lee S, Kim SW, Kang HS. Jung SY, et al. Among authors: lee ks, lee s. J Surg Oncol. 2011 Mar 1;103(3):207-11. doi: 10.1002/jso.21819. Epub 2010 Dec 22. J Surg Oncol. 2011. PMID: 21337548

9

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.

Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW. Im SA, et al. Among authors: lee ks, lee es. Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18. Breast Cancer Res Treat. 2012. PMID: 22094934 Clinical Trial.

10

Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.

Lee KS, Park IH, Nam BH, Ro J. Lee KS, et al. Invest New Drugs. 2013 Feb;31(1):152-9. doi: 10.1007/s10637-012-9824-8. Epub 2012 May 5. Invest New Drugs. 2013. PMID: 22562702 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,178 results

Search Page